Long-term safety of topical bacteriophage application to the frontal sinus region

Frontiers in Cellular and Infection Microbiology

Volumn 7, Issue FEB, 2017, Pages

  Drilling, Amanda J ^a   Ooi, Mian L ^a   Miljkovic, Dijana ^a   James, Craig ^b   Speck, Peter ^c   Vreugde, Sarah ^a   Clark, Jason ^d   Wormald, Peter John ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Adelaide Pathology Partners   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d Fixed Phage Limited   (United Kingdom)

Author keywords

Bacteriophage; Cilia; Inflammation; Staphylococcus aureus; Therapeutic safety; Topical

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; CELL HYPERPLASIA; CONTROLLED STUDY; DISK DIFFUSION; FRONTAL SINUS; HISTOLOGY; LATEX AGGLUTINATION TEST; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PARANASAL SINUS; PHAGE THERAPY; PLAQUE ASSAY; PULSED FIELD GEL ELECTROPHORESIS; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; HOST RANGE; MICROBIOLOGY; NOSE MUCOSA; PATHOLOGY; PHYSIOLOGY; PROCEDURES; SHEEP; SINUSITIS; STAPHYLOCOCCUS PHAGE; TOPICAL DRUG ADMINISTRATION; VIROLOGY;

ADMINISTRATION, TOPICAL; ANIMALS; DISEASE MODELS, ANIMAL; FRONTAL SINUS; HOST SPECIFICITY; NASAL MUCOSA; PHAGE THERAPY; SHEEP; SINUSITIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES;

EID: 85014606716     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2017.00049     Document Type: Article

References (56)

1. Anwar, H., Dasgupta, M. K., and Costerton, J. W. (1990). Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob. Agents Chemother. 34, 2043-2046. doi: 10.1128/AAC.34.11.2043
2. Baldoni, D., Haschke, M., Rajacic, Z., Zimmerli, W., and Trampuz, A. (2009). Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 53, 1142-1148. doi: 10.1128/AAC.00775-08
3. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., et al. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204-210. doi: 10.1128/IAI.70.1.204-210.2002
4. Bode, L. G., Kluytmans, J. A., Wertheim, H. F., Bogaers, D., Vandenbroucke-Grauls, C. M., Roosendaal, R., et al. (2010). Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362, 9-17. doi: 10.1056/NEJMoa0808939
5. Bruttin, A., and Brussow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878. doi: 10.1128/AAC.49.7.2874-2878.2005
6. Carlton, R. M. (1999). Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. 47, 267-274.
7. Carson, L., Gorman, S. P., and Gilmore, B. F. (2010). The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol. Med. Microbiol. 59, 447-455. doi: 10.1111/j.1574-695X.2010.00696.x
8. Cerca, N., Oliveira, R., and Azeredo, J. (2007). Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K. Lett. Appl. Microbiol. 45, 313-317. doi: 10.1111/j.1472-765X.2007.02190.x
9. Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future microbiol. 8, 769-783. doi: 10.2217/fmb.13.47
10. Chen, A. F., Wessel, C. B., and Rao, N. (2013). Staphylococcus aureus screening and decolonization in orthopaedic surgery and reduction of surgical site infections. Clin. Orthop. Relat. Res. 471, 2383-2399. doi: 10.1007/s11999-013-2875-0
11. CLSI (2012). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. M02-A11, Vol. 32. Wayne: Clinical and Laboratory Standards Institute.
12. Corbin, B. D., McLean, R. J., and Aron, G. M. (2001). Bacteriophage T4 multiplication in a glucose-limited Escherichia coli biofilm. Can. J. Microbiol. 47, 680-684. doi: 10.1139/cjm-47-7-680
13. Curtin, J. J., and Donlan, R. M. (2006). Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob. Agents Chemother. 50, 1268-1275. doi: 10.1128/AAC.50.4.1268-1275.2006
14. Doolittle, M. M., Cooney, J. J., and Caldwell, D. E. (1995). Lytic infection of Escherichia coli biofilms by bacteriophage T4. Can. J. Microbiol. 41, 12-18. doi: 10.1139/m95-002
15. Drilling, A. J., Cooksley, C., Chan, C., Wormald, P. J., and Vreugde, S. (2016). Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme. Int. Forum Allergy Rhinol. 6, 349-355. doi: 10.1002/alr.21680
16. Drilling, A., Morales, S., Boase, S., Jervis-Bardy, J., James, C., Jardeleza, C., et al. (2014a). Safety and efficacy of topical bacteriophage and ethylenediaminetetraacetic acid treatment of Staphylococcus aureus infection in a sheep model of sinusitis. Int. Forum Allergy Rhinol. 4, 176-186. doi: 10.1002/alr.21270
17. Drilling, A., Morales, S., Jardeleza, C., Vreugde, S., Speck, P., and Wormald, P. J. (2014b). Bacteriophage reduces biofilm of Staphylococcus aureus ex vivo isolates from chronic rhinosinusitis patients. Am. J. Rhinol. Allergy 28, 3-11. doi: 10.2500/ajra.2014.28.4001
18. Foreman, A., and Wormald, P. J. (2010). Different biofilms, different disease? a clinical outcomes study. Laryngoscope 120, 1701-1706. doi: 10.1002/lary.21024
19. Fu, W., Forster, T., Mayer, O., Curtin, J. J., Lehman, S. M., and Donlan, R. M. (2010). Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother. 54, 397-404. doi: 10.1128/AAC.00669-09
20. Ha, K. R., Psaltis, A. J., Tan, L., and Wormald, P. J. (2007). A sheep model for the study of biofilms in rhinosinusitis. Am. J. Rhinol. 21, 339-345. doi: 10.2500/ajr.2007.21.3032
21. Hawkins, C., Harper, D., Burch, D., Anggard, E., and Soothill, J. (2010). Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet. Microbiol. 146, 309-313. doi: 10.1016/j.vetmic.2010.05.014
22. Jervis-Bardy, J., and Wormald, P. J. (2012). Microbiological outcomes following mupirocin nasal washes for symptomatic, Staphylococcus aureus-positive chronic rhinosinusitis following endoscopic sinus surgery. Int. Forum Allergy Rhinol. 2, 111-115. doi: 10.1002/alr.20106
23. Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Wettig, S., and Slavcev, R. (2012). Immunocompatibility of bacteriophages as nanomedicines. J. Nanotechnol. 2012:247427. doi: 10.1155/2012/247427
24. Khan Mirzaei, M., Haileselassie, Y., Navis, M., Cooper, C., Sverremark-Ekstrom, E., and Nilsson, A. S. (2016). Morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release In vitro. Front. Microbiol. 7:437. doi: 10.3389/fmicb.2016.00437
25. Kucharewicz-Krukowska, A., and Slopek, S. (1987). Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. 35, 553-561.
26. Lu, T. K., and Collins, J. J. (2007). Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 104, 11197-11202. doi: 10.1073/pnas.0704624104
27. Lusiak-Szelachowska, M., Zaczek, M., Weber-Dabrowska, B., Miedzybrodzki, R., Letkiewicz, S., Fortuna, W., et al. (2017). Antiphage activity of sera during phage therapy in relation to its outcome. Future Microbial. 12, 109-117. doi: 10.2217/fmb-2016-0156
28. Markoishvili, K., Tsitlanadze, G., Katsarava, R., Morris, J. G. Jr., and Sulakvelidze, A. (2002). A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41, 453-458. doi: 10.1046/j.1365-4362.2002.01451.x
29. McCallin, S., Alam Sarker, S., Barretto, C., Sultana, S., Berger, B., Huq, S., et al. (2013). Safety analysis of a Russian phage cocktail: from MetaGenomic analysis to oral application in healthy human subjects. Virology 443, 187-196. doi: 10.1016/j.virol.2013.05.022
30. McVay, C. S., Velasquez, M., and Fralick, J. A. (2007). Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51, 1934-1938. doi: 10.1128/AAC.01028-06
31. Miedzybrodzki, R., Switala-Jelen, K., Fortuna, W., Weber-Dabrowska, B., Przerwa, A., Lusiak-Szelachowska, M., et al. (2008). Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 131, 233-242. doi: 10.1016/j.virusres.2007.09.013
32. Miernikiewicz, P., Dabrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielinska, J., et al. (2013). T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS ONE 8:e71036. doi: 10.1371/journal.pone.0071036
33. Mousa, H. A. (2005). Burn and scald injuries. East. Mediterr. Health J. 11, 1099-1109.
34. O'Brien, F. G., Udo, E. E., and Grubb, W. B. (2006). Contour-clamped homogeneous electric field electrophoresis of Staphylococcus aureus. Nature protoc. 1, 3028-3033. doi: 10.1038/nprot.2006.382
35. O'Flaherty, S., Coffey, A., Edwards, R., Meaney, W., Fitzgerald, G. F., and Ross, R. P. (2004). Genome of Staphylococcal phage K: a new lineage of Myoviridae infecting gram-positive bacteria with a low G+C content. J. Bacteriol. 186, 2862-2871. doi: 10.1128/JB.186.9.2862-2871.2004
36. Park, K., Cha, K. E., and Myung, H. (2014). Observation of inflammatory responses in mice orally fed with bacteriophage T7. J. Appl. Microbiol. 117, 627-633. doi: 10.1111/jam.12565
37. Perl, T. M., and Roy, M. C. (1995). Postoperative wound infections: risk factors and role of Staphylococcus aureus nasal carriage. J. Chemother. 7(Suppl. 3), 29-35.
38. Petti, C. A., Fowler, V. G. Jr. (2003). Staphylococcus aureus bacteremia and endocarditis. Cardiol. Clin. 21, 219-233.
39. Piraino, B. (2000). Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J. 46, S13-S17. doi: 10.1097/00002480-200011000-00031
40. Przerwa, A., Zimecki, M., Switala-Jelen, K., Dabrowska, K., Krawczyk, E., Luczak, M., et al. (2006). Effects of bacteriophages on free radical production and phagocytic functions. Med. Microbiol. Immun. 195, 143-150. doi: 10.1007/s00430-006-0011-4
41. Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., and Sulakvelidze, A. (2009). Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18, 237-238, 240-233. doi: 10.12968/jowc.2009.18.6.42801
42. Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., et al. (2015). The global threat of antimicrobial resistance: science for intervention. N. Microbes N. Infect. 6, 22-29. doi: 10.1016/j.nmni.2015.02.007
43. Sarker, S. A., McCallin, S., Barretto, C., Berger, B., Pittet, A. C., Sultana, S., et al. (2012). Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434, 222-232. doi: 10.1016/j.virol.2012.09.002
44. Sillankorva, S., Oliveira, R., Vieira, M. J., Sutherland, I. W., and Azeredo, J. (2004). Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 20, 133-138. doi: 10.1080/08927010410001723834
45. Singhal, D., Foreman, A., Bardy, J. J., and Wormald, P. (2011). J. Staphylococcus aureus biofilms: nemesis of endoscopic sinus surgery. Laryngoscope 121, 1578-1583. doi: 10.1002/lary.21805
46. Singhal, D., Psaltis, A. J., Foreman, A., and Wormald, P. J. (2010). The impact of biofilms on outcomes after endoscopic sinus surgery. Am. J. Rhinol. Allergy 24, 169-174. doi: 10.2500/ajra.2010.24.3462
47. Soothill, J. S. (1994). Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 20, 209-211. doi: 10.1016/0305-4179(94)90184-8
48. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. Jr. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
49. Tait, K., Skillman, L. C., and Sutherland, I. W. (2002). The efficacy of bacteriophage as a method of biofilm eradication. Biofouling 18, 305-311. doi: 10.1080/0892701021000034418
50. Takac, M., and Blasi, U. (2005). Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 2934-2940. doi: 10.1128/AAC.49.7.2934-2940.2005
51. Theodorsson-Norheim, E. (1986). Kruskal-Wallis test: BASIC computer program to perform nonparametric one-way analysis of variance and multiple comparisons on ranks of several independent samples. Comput. Methods Programs Biomed 23, 57-62. doi: 10.1016/0169-2607(86)90081-7
52. Vybiral, D., Takac, M., Loessner, M., Witte, A., von Ahsen, U., and Blasi, U. (2003). Complete nucleotide sequence and molecular characterization of two lytic Staphylococcus aureus phages: 44AHJD and P68. FEMS Microbiol. Lett. 219, 275-283. doi: 10.1016/S0378-1097(03)00028-4
53. Wills, Q. F., Kerrigan, C., and Soothill, J. S. (2005). Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob. Agents Chemother. 49, 1220-1221. doi: 10.1128/AAC.49.3.1220-1221.2005
54. Wright, A., Hawkins, C. H., Anggard, E. E., and Harper, D. R. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357. doi: 10.1111/j.1749-4486.2009.01973.x
55. Zaczek, M., Lusiak-Szelachowska, M., Jonczyk-Matysiak, E., Weber-Dabrowska, B., Miedzybrodzki, R., Owczarek, B., et al. (2016). Antibody production in response to staphylococcal ms-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 7:1681. doi: 10.3389/fmicb.2016.01681
56. Ziran, B. H. (2007). Osteomyelitis. J. Trauma. 62(6 Suppl.), S59-S60. doi: 10.1097/TA.0b013e318065abbd